Among the locally rearranged types, which account for 30% of all pancreatic cancers, there are cases that show amplification of the protooncogenes such as ERBB2, MET, fibroblast growth factor receptor 1 (FGFR1), cell division protein kinase 6 (CDK6), phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which are likely to be treated by molecular targeted therapies. This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.